| Phase 02 trials |
|
Phase 0
|
NCT03361800 |
Nov 2018 → Sep 2019 |
invasive breast carcinoma, triple-negative breast carcinoma |
UNC Lineberger Comprehensive Cancer Center |
Terminated
|
No outcome recorded
|
|
Phase 0
|
NCT03018249 |
Oct 2017 → Apr 2018 |
endometrial endometrioid adenocarcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
| Phase 126 trials |
|
Phase 1
|
NCT04296942 |
May → Oct 2021 |
HER2 positive breast carcinoma, triple-negative breast carcinoma |
National Cancer Institute (NCI) |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT04631029 |
Apr → Dec 2021 |
metastatic malignant neoplasm in the brain, small cell lung carcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03760614 |
Jan 2021 → Jul 2022 |
pancreatic adenocarcinoma |
Abramson Cancer Center at Penn Medicine |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT03924245 |
Oct 2020 → Feb 2022 |
fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma +5 |
Vanderbilt-Ingram Cancer Center |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03925428 |
Sep 2020 |
T-cell non-Hodgkin lymphoma, adult lymphoma, aggressive B-cell non-Hodgkin lymphoma, pancreatic adenocarcinoma +1 |
National Cancer Institute (NCI) |
Withdrawn
|
No outcome recorded
|
|
Phase 1
|
NCT03829930 |
May 2019 → Sep 2020 |
prostate adenocarcinoma |
George Washington University |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03473639 |
Jan 2019 → Sep 2021 |
breast cancer |
University of Virginia |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03215264 |
Oct 2017 → Jun 2020 |
colorectal cancer |
Abramson Cancer Center at Penn Medicine |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03192111 |
Jul → Nov 2017 |
impaired renal function disease |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02936752 |
Jun 2017 → Nov 2022 |
myelodysplastic syndrome |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT03187015 |
May → Jun 2017 |
— |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02780804 |
Jan 2017 → Jun 2021 |
brainstem neoplasm, lymphoma, optic pathway glioma, pineal body neoplasm |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02922946 |
Oct 2016 → May 2017 |
— |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02833155 |
Aug 2016 → Jul 2018 |
breast cancer |
Taizhou EOC Pharma Co., Ltd. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02453620 |
Feb 2016 → Apr 2021 overdue |
breast adenocarcinoma, female breast carcinoma, invasive breast carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT02623751 |
Nov 2015 → Oct 2020 |
breast cancer |
Kyowa Kirin, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01886573 |
Jun 2013 → Feb 2015 |
non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT01594398 |
May 2012 → Apr 2014 |
estrogen-receptor positive breast cancer, non-small cell lung carcinoma |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01434303 |
Jan 2012 → Feb 2016 |
HER2 positive breast carcinoma, invasive breast carcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT01159301 |
Jun 2010 → Sep 2013 |
acute basophilic leukemia, acute megakaryoblastic leukemia, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8 |
National Cancer Institute (NCI) |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT01132573 |
Apr 2010 → Jun 2014 |
acute biphenotypic leukemia, adult acute lymphoblastic leukemia |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00754312 |
Jun 2008 → Feb 2009 |
breast cancer |
Syndax Pharmaceuticals |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT00101179 |
Nov 2004 → Apr 2011 |
acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00098891 |
Oct 2004 → Mar 2008 |
Burkitt lymphoma, Hodgkins lymphoma, MALT lymphoma, Waldenstrom macroglobulinemia +13 |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00020579 |
Mar 2001 → Apr 2008 |
cancer |
National Institutes of Health Clinical Center (CC) |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT00015925 |
Feb 2001 → ? |
leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative disease, plasma cell neoplasm |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
| Phase 1/213 trials |
|
Phase 1/2
|
NCT07261592 |
Dec 2025 → Sep 2028 expected |
urinary bladder cancer |
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT07708194 |
Jun 2025 → Feb 2027 expected |
HER2 positive breast carcinoma, hormone receptor-positive breast cancer |
Tianjin Medical University Cancer Institute and Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT05898828 |
Aug 2024 |
esophageal cancer |
National Cancer Institute (NCI) |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT05053971 |
Nov 2022 → Jul 2027 expected |
digestive system carcinoma, metastatic carcinoma, refractory malignant neoplasm |
National Cancer Institute (NCI) |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT04708470 |
Oct 2021 → Nov 2026 expected |
anus cancer, cervical cancer, human papilloma virus infection, oropharyngeal carcinoma +3 |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03838042 |
May 2020 → Jun 2026 overdue |
central nervous system neoplasm |
University Hospital Heidelberg |
Recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT03280563 |
Dec 2017 → Sep 2024 |
breast neoplasm |
Hoffmann-La Roche |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT03024437 |
Jun 2017 → Jun 2024 |
metastatic malignant neoplasm, renal cell carcinoma |
Roberto Pili |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT02437136 |
Aug 2015 → Sep 2022 |
colorectal cancer, melanoma, non-small cell lung carcinoma |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT01383447 |
Oct 2010 → Apr 2012 |
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia |
National Cancer Institute (NCI) |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT01038778 |
Oct 2009 → May 2019 overdue |
clear cell renal carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|
|
Phase 1/2
|
NCT00602030 |
Jan 2008 → Feb 2010 |
non-small cell lung carcinoma |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 1/2
|
NCT00387465 |
Aug 2006 → May 2014 |
non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
| Phase 227 trials |
|
Phase 2
|
NCT07441486 |
Apr 2026 overdue |
breast cancer |
Tianjin Medical University Cancer Institute and Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07235618 |
Jan 2026 → Jan 2028 expected |
breast cancer |
Sun Yat-sen University |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT07330544 |
Nov 2025 → Nov 2027 expected |
breast cancer |
Zhejiang Cancer Hospital |
Recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03978624 |
Sep 2020 → Mar 2024 overdue |
urinary bladder cancer |
UNC Lineberger Comprehensive Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03765229 |
Mar 2019 → Dec 2022 |
melanoma |
UNC Lineberger Comprehensive Cancer Center |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03552380 |
Jul 2018 → Jun 2022 |
renal cell carcinoma |
Roberto Pili |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03501381 |
May 2018 → Jan 2023 overdue |
renal cell carcinoma |
Roberto Pili |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT02697630 |
Feb 2018 → Jan 2023 |
uveal melanoma |
Vastra Gotaland Region |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03211988 |
Dec 2017 → Aug 2021 |
digestive system neuroendocrine neoplasm |
Antonio Fojo |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT03250273 |
Nov 2017 → Nov 2020 |
cholangiocarcinoma, malignant pancreatic neoplasm |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03291886 |
Sep 2017 → Apr 2019 |
breast cancer |
Kyowa Kirin, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT03179930 |
Jun 2017 → Jun 2026 overdue |
lymphoma |
Memorial Sloan Kettering Cancer Center |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT02115594 |
Apr 2014 → Dec 2015 |
breast cancer |
Syndax Pharmaceuticals |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT01928576 |
Nov 2013 → Apr 2023 |
non-small cell lung carcinoma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01935947 |
May 2013 → Apr 2017 |
non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01349959 |
Aug 2011 → Mar 2014 |
male breast carcinoma, triple-negative breast carcinoma |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT01305499 |
Jul 2011 → Sep 2021 |
acute myeloid leukemia |
Hetty Carraway |
Unknown
|
No outcome recorded
|
|
Phase 2
|
NCT01234532 |
Oct 2010 → May 2017 |
female breast carcinoma, triple-negative breast carcinoma |
University of Maryland, Baltimore |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01207726 |
Sep 2010 → May 2013 |
non-small cell lung carcinoma |
National Cancer Institute (NCI) |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT01105377 |
Apr 2010 → Mar 2012 |
rectal cancer |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00866333 |
Apr 2009 → Feb 2013 |
Hodgkins lymphoma |
Syndax Pharmaceuticals |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00828854 |
Oct 2008 → Nov 2009 |
estrogen-receptor positive breast cancer |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00750698 |
Aug 2008 → May 2010 |
non-small cell lung carcinoma |
Syndax Pharmaceuticals |
Terminated
|
No outcome recorded
|
|
Phase 2
|
NCT00676663 |
Jun 2008 → Jan 2011 |
estrogen-receptor positive breast cancer |
Syndax Pharmaceuticals |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00462605 |
Apr 2007 → Mar 2011 |
acute erythroid leukemia, acute megakaryoblastic leukemia in adult, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +12 |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00313586 |
Aug 2006 → Jul 2013 |
acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent, acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia with t(9;11)(p22;q23), acute myeloid leukemia, inv(16)(p13.1;q22) +4 |
National Cancer Institute (NCI) |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT00185302 |
Dec 2004 → Jul 2006 |
melanoma |
Bayer |
Completed
|
No outcome recorded
|
|
| Phase 31 trial |
|
Phase 3
|
NCT02115282 |
Mar 2014 → May 2020 overdue |
Her2-receptor negative breast cancer, breast adenocarcinoma, female breast carcinoma |
National Cancer Institute (NCI) |
Active not recruiting
|
No outcome recorded
|